The phase 3 BREAKWATER trial shows that a targeted combination of encorafenib (Braftovi), cetuximab (Erbitux), and FOLFIRI chemotherapy significantly improves outcomes for patients with previously untreated BRAF V600E–mutant metastatic colorectal cancer. The regimen is now considered a new standard of care following FDA traditional approval in February 2026.
The study enrolled 147 patients and compared the triplet targeted regimen against standard FOLFIRI with or without bevacizumab. Patients receiving the encorafenib-based combination achieved a median progression-free survival of 15.2 months versus 8.3 months with standard therapy, reducing the risk of disease progression or death by 56%. Median overall survival was not yet reached in the experimental arm compared with 20.3 months in the control group. The 18-month survival rate was 72.0% versus 54.9%, and the objective response rate was 64.4% compared with 39.2%.
The benefit was consistent across all major patient subgroups, including tumor location and presence of liver metastases. Although grade 3–4 adverse events were slightly lower in the experimental arm, treatment discontinuation rates were comparable between groups. Common side effects included gastrointestinal symptoms, fatigue, anemia, and neutropenia.